Peginterferon alfa-2b + ribavirin
Alternative Names: Cotronak + peginterferon alfa-2b; PEG interferon-alpha-2b + ribavirin; PEG-Intron + REBETOL; PEG-Rebetron; Pegetron; Pegylated interferon-alpha-2b + ribavirin; Ribavirin + peginterferon alfa-2b; SCH-54031 + SCH-18908Latest Information Update: 17 Sep 2021
Price :
$50 *
At a glance
- Originator Schering-Plough
- Developer Merck & Co
- Class Antivirals; Interferons; Nucleosides
- Mechanism of Action Enzyme inhibitors; Immunostimulants; Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis C
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 09 Apr 2015 Merck Sharp & Dohme terminates phase III trial in Hepatitis C (in type C compensated liver cirrhosis patients) in Japan (NCT00811967)
- 17 Jul 2013 The UK's National Institute for Health and Care Excellence issues draft guidance recommending peginterferon alfa-2b in combination with ribavirin for Hepatitis C (in children, in adolescents)